SCHEMBL6715492

SCHEMBL6715492

O=C(O)c1ccc(CN2CCC(NC(=O)c3ccccc3-c3ccc(OC(F)(F)F)cc3)CC2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 3/20 0.56
▸ PRKAA2 P54646 6/20 0.51
▸ PRKAB2 O43741 3/20 0.51
▸ PRKAG1 P54619 3/20 0.51
▸ PRKAA1 Q13131 3/20 0.51
▸ PRKAG3 Q9UGI9 3/20 0.51
▸ PRKAG2 Q9UGJ0 3/20 0.51
▸ PRKAB1 Q9Y478 3/20 0.51
▸ CHRM2 P08172 2/20 0.49
▸ CHRM1 P11229 2/20 0.49
▸ SSTR5 P35346 1/20 0.48
▸ BCHE P06276 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ BACE1 P56817 1/20 0.48
▸ DRD4 P21917 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ CHRM5 P08912 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ CHRM4 P08173 2/20 0.47
▸ SLC6A5 Q9Y345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715786 0.88 CCR3 (0.62) CCR3CHRM2CHRM1BCHEACHE
SCHEMBL6714432 0.86 SLC6A5 (0.57) CCR3CHRM2CHRM1SSTR5BCHE
SCHEMBL18286595 0.81 SMO (0.54) CCR3PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL18286601 0.81 SMO (0.53) CCR3PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL18286588 0.81 SMO (0.53) CCR3PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL6719419 0.80 CCR3 (0.51) CCR3CHRM2CHRM1SSTR5DRD4
SCHEMBL16812619 0.80 SMO (0.48) CCR3PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL6716204 0.79 CCR3 (0.48) CCR3CHRM2CHRM1SSTR5DRD4
SCHEMBL6714169 0.79 CCR3 (0.48) CCR3CHRM2CHRM1SSTR5DRD4
SCHEMBL16812616 0.79 PRKAB2 (0.49) CCR3PRKAA2PRKAB2PRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034028-A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors MERCK PATENT GMBH (DE) 2004-02-19 — — US disclosed
EP-1335912-A1 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS MERCK PATENT GmbH (DE) 2003-08-20 — — EP disclosed
WO-2002042291-A1 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS MERCK PATENT GMBH (DE) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034028-A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors LIPC, CETP, MTTP CCR3 2275/4885PRKAA2 3558/4885PRKAB2 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback